| 产品详情 |
| Edit |   |
|---|
| Product Name | XL184 |
|---|
| Description | Purity >98%. XL184 is a pan tyrosine kinase inhibitor that primarily targets VEGFR2 (IC50 = 0.035 nM) and c-Met (IC50 = 1.3 nM) but also inhibits RET, c-Kit, Axl, FLT3, and Tie2 (IC50 s = 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively). In in vivo breast, lung, and glioma tumor models that represent dysregulated c-Met and VEGFR signaling, XL184 was shown to reduce tumor and endothelial cell proliferation, inhibiting both angiogenesis and metastasis. XL184 has undergone clinical trial in a broad number of cancers, including thyroid carcinoma, prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma, and glioblastoma. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, BMS-907351, Cabozantinib |
|---|
| Gene, Accession, CAS # | CAS: 849217-68-1 |
|---|
| Catalog # | LS-H10528 |
|---|
| Price | |
|---|
| Order / More Info | XL184 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|